Cargando…

SUN-349 Prognostic Metabolic Signature in Aggressive Adrenocortical Carcinoma

Introduction Adrenocortical carcinoma (ACC) is a rare and aggressive disease with high mortality rate, lack of effective medical therapy, and high recurrence rate even with complete resection. Prognostic biomarkers are needed to guide treatment. The aim of this study was to identify prognostic tissu...

Descripción completa

Detalles Bibliográficos
Autores principales: Tirosh, Amit, Boufraqech, Myriem, Nilubol, Naris, Kebebew, Electron, Patel, Dhaval
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Endocrine Society 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552828/
http://dx.doi.org/10.1210/js.2019-SUN-349
_version_ 1783424678010814464
author Tirosh, Amit
Boufraqech, Myriem
Nilubol, Naris
Kebebew, Electron
Patel, Dhaval
author_facet Tirosh, Amit
Boufraqech, Myriem
Nilubol, Naris
Kebebew, Electron
Patel, Dhaval
author_sort Tirosh, Amit
collection PubMed
description Introduction Adrenocortical carcinoma (ACC) is a rare and aggressive disease with high mortality rate, lack of effective medical therapy, and high recurrence rate even with complete resection. Prognostic biomarkers are needed to guide treatment. The aim of this study was to identify prognostic tissue metabolites and dysregulated pathways to guide treatment. Patients and methods In this study seventeen tumors from patients with advanced metastatic ACC were analyzed through an Ultra High-Performance Liquid Chromatography-Tandem Mass Spectroscopy to detect and identify known and unknown metabolites. Kaplan Meier survival analyses were performed separating patients with high and low levels of each metabolite by median values. A pathway and enrichment analysis utilizing the top 100 small molecules associated with survival was performed through MetaboAnalyst software. Results 841 metabolites were detected. Survival analysis identified 15 metabolites that were prognostic. Eleven known metabolites were identified including N-acetylglutamine, 1-methylhistamine, palmitoyl-linleoyl-glycerol, corticosterone, 2-palmitoyl-GPC, pregnen-diol, androstenediol, and 5,6-dihydrouracil. Three metabolites were found to be independently prognostic in a multivariable analysis: 3-methoxytyrosine (hazard ratio [HR] 36.0, p=0.005), taurocholenate (HR 48.3, p=0.004), and 21-hydroxypregnenolone (HR 7.0, p=0.02). Four adrenocortical steroid synthesis metabolites were significantly different between patients alive vs. dead at the end of follow-up. A pathway and enrichment analysis identified the linoleic acid metabolism pathway to be significantly enriched (p=0.025) with the highest impact coefficient (0.66). Four metabolites in the Linoleic acid pathway were detected: lecithin, linoleic acid, gamma-Linolenic acid and 12,13-dihydroxyoctadec-9-enoic acid (12,13-DiHOME). Among them lecithin, linoleic acid and gamma-Linolenic acid levels were lower while 12,13-DiHOME levels were higher among patients with a higher risk to die of their disease during follow-up (fold change values of 0.73, 0.13, 0.44 and 1.52, respectively). Conclusions In conclusion, an analysis of the tissue metabolome identified a metabolomic signature that was prognostic for overall survival. Furthermore, a metabolomic analysis of adrenocortical carcinoma suggests a pivotal role for the linoleic acid pathway in determining patients’ prognosis.
format Online
Article
Text
id pubmed-6552828
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Endocrine Society
record_format MEDLINE/PubMed
spelling pubmed-65528282019-06-13 SUN-349 Prognostic Metabolic Signature in Aggressive Adrenocortical Carcinoma Tirosh, Amit Boufraqech, Myriem Nilubol, Naris Kebebew, Electron Patel, Dhaval J Endocr Soc Adrenal Introduction Adrenocortical carcinoma (ACC) is a rare and aggressive disease with high mortality rate, lack of effective medical therapy, and high recurrence rate even with complete resection. Prognostic biomarkers are needed to guide treatment. The aim of this study was to identify prognostic tissue metabolites and dysregulated pathways to guide treatment. Patients and methods In this study seventeen tumors from patients with advanced metastatic ACC were analyzed through an Ultra High-Performance Liquid Chromatography-Tandem Mass Spectroscopy to detect and identify known and unknown metabolites. Kaplan Meier survival analyses were performed separating patients with high and low levels of each metabolite by median values. A pathway and enrichment analysis utilizing the top 100 small molecules associated with survival was performed through MetaboAnalyst software. Results 841 metabolites were detected. Survival analysis identified 15 metabolites that were prognostic. Eleven known metabolites were identified including N-acetylglutamine, 1-methylhistamine, palmitoyl-linleoyl-glycerol, corticosterone, 2-palmitoyl-GPC, pregnen-diol, androstenediol, and 5,6-dihydrouracil. Three metabolites were found to be independently prognostic in a multivariable analysis: 3-methoxytyrosine (hazard ratio [HR] 36.0, p=0.005), taurocholenate (HR 48.3, p=0.004), and 21-hydroxypregnenolone (HR 7.0, p=0.02). Four adrenocortical steroid synthesis metabolites were significantly different between patients alive vs. dead at the end of follow-up. A pathway and enrichment analysis identified the linoleic acid metabolism pathway to be significantly enriched (p=0.025) with the highest impact coefficient (0.66). Four metabolites in the Linoleic acid pathway were detected: lecithin, linoleic acid, gamma-Linolenic acid and 12,13-dihydroxyoctadec-9-enoic acid (12,13-DiHOME). Among them lecithin, linoleic acid and gamma-Linolenic acid levels were lower while 12,13-DiHOME levels were higher among patients with a higher risk to die of their disease during follow-up (fold change values of 0.73, 0.13, 0.44 and 1.52, respectively). Conclusions In conclusion, an analysis of the tissue metabolome identified a metabolomic signature that was prognostic for overall survival. Furthermore, a metabolomic analysis of adrenocortical carcinoma suggests a pivotal role for the linoleic acid pathway in determining patients’ prognosis. Endocrine Society 2019-04-30 /pmc/articles/PMC6552828/ http://dx.doi.org/10.1210/js.2019-SUN-349 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Adrenal
Tirosh, Amit
Boufraqech, Myriem
Nilubol, Naris
Kebebew, Electron
Patel, Dhaval
SUN-349 Prognostic Metabolic Signature in Aggressive Adrenocortical Carcinoma
title SUN-349 Prognostic Metabolic Signature in Aggressive Adrenocortical Carcinoma
title_full SUN-349 Prognostic Metabolic Signature in Aggressive Adrenocortical Carcinoma
title_fullStr SUN-349 Prognostic Metabolic Signature in Aggressive Adrenocortical Carcinoma
title_full_unstemmed SUN-349 Prognostic Metabolic Signature in Aggressive Adrenocortical Carcinoma
title_short SUN-349 Prognostic Metabolic Signature in Aggressive Adrenocortical Carcinoma
title_sort sun-349 prognostic metabolic signature in aggressive adrenocortical carcinoma
topic Adrenal
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552828/
http://dx.doi.org/10.1210/js.2019-SUN-349
work_keys_str_mv AT tiroshamit sun349prognosticmetabolicsignatureinaggressiveadrenocorticalcarcinoma
AT boufraqechmyriem sun349prognosticmetabolicsignatureinaggressiveadrenocorticalcarcinoma
AT nilubolnaris sun349prognosticmetabolicsignatureinaggressiveadrenocorticalcarcinoma
AT kebebewelectron sun349prognosticmetabolicsignatureinaggressiveadrenocorticalcarcinoma
AT pateldhaval sun349prognosticmetabolicsignatureinaggressiveadrenocorticalcarcinoma